Considerations for Developing an Autologous Induced Pluripotent Stem Cell (iPSC)-Derived Retinal Pigment Epithelium (RPE) Replacement Therapy
Cold Spring Harbor Perspectives in Medicine · 2024-03 · 14 (3) · a041295
DOI: 10.1101/cshperspect.a041295 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cold Spring Harbor Perspectives in Medicine, online erschienen am 24.07.2023. Verfasst von Devika Bose und 4 weiteren Autor:innen. Beteiligte Einrichtung: Ocular and Stem Cell Translational Research, National Eye Institute, National Institutes of Health, Bethesda, Maryland 20892, USA. Hauptthemen laut MEDLINE: Induced Pluripotent Stem Cells. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Cell-replacement therapies are a new class of treatments, which include induced pluripotent stem cell (iPSC)-derived tissues that aim to replace degenerated cells. iPSCs can potentially be used to generate any cell type of the body, making them a powerful tool for treating degenerative diseases. Cell replacement for retinal degenerative diseases is at the forefront of cell therapies, given the accessibility of the eye for surgical procedures and a huge unmet medical need for retinal degenerative diseases with no current treatment options. Clinical trials are ongoing in different parts of the world using stem cell-derived retinal pigment epithelium (RPE). This review focuses on scientific and regulatory considerations when developing an iPSC-derived RPE cell therapy from the development of a robust and efficient differentiation protocol to critical quality control assays for cell validation, the choice of an appropriate animal model for preclinical testing, and the regulatory aspects that dictate the final approval for proceeding to a first-in-human clinical trial.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Ocular and Stem Cell Translational Research, National Eye Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
- Ocular and Stem Cell Translational Research, National Eye Institute, National Institutes of Health, Bethesda, Maryland 20892, USA Kapil.bharti@nih.gov.
Zitieren
APA
Bose, D., Ortolan, D., Farnoodian, M., Sharma, R., & Bharti, K. (2024). Considerations for Developing an Autologous Induced Pluripotent Stem Cell (iPSC)-Derived Retinal Pigment Epithelium (RPE) Replacement Therapy. Cold Spring Harbor Perspectives in Medicine, 14(3), a041295. https://doi.org/10.1101/cshperspect.a041295
Vancouver
Bose D, Ortolan D, Farnoodian M, Sharma R, Bharti K. Considerations for Developing an Autologous Induced Pluripotent Stem Cell (iPSC)-Derived Retinal Pigment Epithelium (RPE) Replacement Therapy. Cold Spring Harbor Perspectives in Medicine. 2024;14(3):a041295. doi:10.1101/cshperspect.a041295
BibTeX
@article{Bose2024,
author = {Bose, Devika and Ortolan, Davide and Farnoodian, Mitra and Sharma, Ruchi and Bharti, Kapil},
title = {Considerations for Developing an Autologous Induced Pluripotent Stem Cell (iPSC)-Derived Retinal Pigment Epithelium (RPE) Replacement Therapy},
journal = {Cold Spring Harbor Perspectives in Medicine},
year = {2024},
volume = {14},
number = {3},
pages = {a041295},
doi = {10.1101/cshperspect.a041295}
}
EUVIMED